Outset Medical (NASDAQ:OM) CFO Sells $19,943.77 in Stock

Outset Medical, Inc. (NASDAQ:OM) CFO Renee Gaeta sold 4,543 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $4.39, for a total transaction of $19,943.77. Following the completion of the sale, the chief financial officer directly owned 180,840 shares of the company’s stock, valued at $793,887.60. This trade represents a 2.45% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Renee Gaeta also recently made the following trade(s):

• On Wednesday, June 3rd, Renee Gaeta sold 17,672 shares of Outset Medical stock. The stock was sold at an average price of $4.94, for a total transaction of $87,299.68.

Outset Medical Stock Performance

NASDAQ OM opened at $4.30 on Friday. The company has a 50-day simple moving average of $4.57 and a two-hundred day simple moving average of $4.22. The company has a quick ratio of 4.11, a current ratio of 5.19 and a debt-to-equity ratio of 1.03. Outset Medical, Inc. has a 12-month low of $3.00 and a 12-month high of $16.16. The firm has a market cap of $80.83 million, a price-to-earnings ratio of -1.05 and a beta of 1.96.

Outset Medical (NASDAQ:OM) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%.The company had revenue of $31.64 million during the quarter, compared to analysts’ expectations of $28.97 million. On average, equities analysts forecast that Outset Medical, Inc. will post -3.8 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new position in Outset Medical during the 2nd quarter valued at about $121,000. Marquette Asset Management LLC purchased a new stake in Outset Medical in the 2nd quarter worth approximately $212,000. Renaissance Technologies LLC lifted its holdings in Outset Medical by 391.3% in the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock worth $853,000 after buying an additional 176,870 shares during the period. Sei Investments Co. grew its position in shares of Outset Medical by 15.5% in the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock worth $136,000 after buying an additional 4,738 shares during the last quarter. Finally, BML Capital Management LLC grew its position in shares of Outset Medical by 250.2% in the 1st quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock worth $7,304,000 after buying an additional 1,359,021 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on OM. Weiss Ratings raised Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, TD Cowen reiterated a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.